Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Sandoz Signs a Commercialization Agreement with Shionogi for Rizmoic (naldemedine)

Shots: Sandoz to get commercialization rights for Rizmoic (naldemedine) in Germany, UK and the Netherlands with rights of first refusal for other European markets. Shionogi will be responsible for Rizmoic’s manufacturing & development The focus of the agreement is to enhance Sandoz’s anti-pain portfolio for minimizing the side-effects of opioid use in Europe Rizmoic (naldemedine,0.2mg) […]Read More

Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative

Shots: Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML   The companies will utilize ASCO’s CancerLinQ Discovery database of de-identified cancer patient records to improve understanding of responses in patients, AML treatment patterns, disease progression and opportunities for improved QoL The […]Read More

BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla

Shots: BioAtla to receive $20M upfront, $249M as WW development & regulatory milestones, commercial milestones and royalties in Beigene’s territory (Asia (ex-Japan), Australia and New Zealand). Beigene to get WW co-exclusive & exclusive development & commercialization rights respectively for BioAtla’ BA3071 in combination with Beigene’s tislelizumab Beigene to take care of all development & commercialization […]Read More

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria

Shots: Generium’s biosimilar of Eculizumab is developed using Selexis’ SUREtechnology Platform which is based on Selexis SGE (Selexis Genetic Elements) consist of human DNA based element, controlling the chromatin across mammalian cells Eculizumab is a monoclonal IgG2/4 Ab developed as a fifth biosimilar SUREtechnology Platform involved in reduction of the destruction of red blood cells […]Read More

Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to

Shots: The BLA submission is based on P-III MEDALIST & BELIEVE studies. The P-III MEDALIST study involves assessing of luspatercept (1.0 mg/kg) vs PBO in 229 patients with low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia + RBC transfusion aged ~71yrs across 11 countries The P-III BELIEVE study involves assessing of luspatercept (1.0 mg/kg) + […]Read More